Flow Cytometry is an important analytical and cell purification tool in cancer and immunological research. Modern cancer analysis requires innovative procedures that include both imaging methods and non-imaging analysis, such as that provided by flow cytometry. Flow cytometry allows the isolation of pure cell populations comprising less than 0.01% of a complex mixture. In addition, as an analytical tool it permits statistical analysis of cell population and cell function changes, apoptosis, intracellular protein expression, and gene transfection for example. Innovative methods that contribute to modern cancer research include gene expression detection with green fluorescent protein, parameter cytometry, apoptotic effect of chemotherapy, multi-drug resistance evaluation, and minimal residual disease detection. In addition, the integrated use of cell isolation (by flow cytometry) and downstream assessment of isolated cells (by proteomics or genomics) offers a powerful application of technologies offered by multiple Resources within the Knight Cancer Institute. High quality instrumentation is available to Knight Cancer Institute members in the form of two cell sorters and three analytical instruments. The Flow Cytometry Shared Resource provides consultation, training/teaching, technical expertise, and technical services in flow cytometry to meet the needs of Knight Cancer Institute members.

Public Health Relevance

The Flow Cytometry Shared Resource offers state of the art equipment and support to Knight Cancer Institute researchers studying a wide array of human diseases. The resource positively impacts the study of hematopoietic and non-hematopoietic cancers, infectious diseases, inflammatory diseases, autoimmune diseases, and graft versus host disease;as well as stem cell biology and regenerative medicine.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-16
Application #
8504958
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
16
Fiscal Year
2013
Total Cost
$43,559
Indirect Cost
$23,265
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Chen, Yiyi; Chen, Zunqiu; Mori, Motomi (2016) A new statistical decision rule for single-arm phase II oncology trials. Stat Methods Med Res 25:118-32
Pati, Shibani; Potter, Daniel R; Baimukanova, Gyulnar et al. (2016) Modulating the endotheliopathy of trauma: Factor concentrate versus fresh frozen plasma. J Trauma Acute Care Surg 80:576-84; discussion 584-5
Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703
Tsikitis, Vassiliki L; Potter, Amiee; Mori, Motomi et al. (2016) MicroRNA Signatures of Colonic Polyps on Screening and Histology. Cancer Prev Res (Phila) 9:942-949
Wiedmeier, Julia Erin; Kato, Catherine; Zhang, Zhenzhen et al. (2016) Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women. Exp Hematol 44:857-865.e5
Young, John I; Mongoue-Tchokote, Solange; Wieghard, Nicole et al. (2016) Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer. Dis Colon Rectum 59:306-15
Goodspeed, Andrew; Heiser, Laura M; Gray, Joe W et al. (2016) Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol Cancer Res 14:3-13
Ebrahim, Seham; Avenarius, Matthew R; Grati, M'hamed et al. (2016) Stereocilia-staircase spacing is influenced by myosin III motors and their cargos espin-1 and espin-like. Nat Commun 7:10833
Cambronne, Xiaolu A; Stewart, Melissa L; Kim, DongHo et al. (2016) Biosensor reveals multiple sources for mitochondrial NAD⁺. Science 352:1474-7
Zhang, Zhenzhen; Garzotto, Mark; Beer, Tomasz M et al. (2016) Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial. Nutr Cancer 68:1309-1319

Showing the most recent 10 out of 188 publications